Table 1.
Demographics of the study population.
| DEE Chemoembolization | Radioembolization | P | |
|---|---|---|---|
| Patients (N/total, % total) | 32/58 (56%) | 26/58 (44%) | |
| Age (median, (range)in yrs) | 60 (21–81) | 69 (15–80) | 0.06 |
| Gender (M/F) | 27/5 | 19/7 | 0.34 |
| Index lesion size (median, (range) in cm) | 4 (1–17) | 6.7 (1.7–21.3) | <0.001 |
| Intrahepatic tumor multifocality | 0.12 | ||
| Single tumor | 10/32 | 4/26 | |
| 2–3 tumors | 10/32 | 5/26 | |
| >3 tumors | 12/32 | 17/26 | |
| Presence of extra-hepatic disease (N/total) | 1/32 | 8/26 | 0.007 |
| Presence of ascites (N/total) | 6/32 | 4/26 | 1.0 |
| Presence of vascular invasion (N/total) | 6/32 | 11/26 | 0.08 |
| Presence of lymph node metastasis (N, % total) | 0/32 | 6/26 | 0.005 |
| ADC value (median, (range) in 10−3 mm2/s) | 1.08 (0.528–2.71) | 0.99 (0.42–2.18) | 0.25 |
| ECOG status | 0.42 | ||
| ECOG 0 | 16/32 | 11/26 | |
| ECOG 1 | 14/32 | 15/26 | |
| ECOG 2 | 2/32 | 0/26 | |
| History of hepatic encephalopathy (N, % total) | 3/32 | 0/26 | 0.24 |
| Pre-procedure total bilirubin (median, (range) in mg/dL) | 1 (0.3–2.6) | 0.75 (0.3–2.5) | 0.06 |
| Pre-procedure serum albumin (median, (range) in g/dL) | 4.3 (3.0–5.1) | 4.2 (3.3–5.3) | 0.78 |
| Childs-Pugh score | 0.12 | ||
| Childs-Pugh A | 26/32 | 25/26 | |
| Childs-Pugh B | 6/32 | 1/26 | |
| Childs-Pugh C | 0/32 | 0/26 | |
| BCLC classification | 0.02 | ||
| BCLC A | 7/32 | 0/26 | |
| BCLC B | 7/32 | 5/26 | |
| BCLC C | 18/32 | 21/26 |
DEE: drug eluting embolic, ADC: apparent diffusion coefficient, ECOG: extra-hepatic metastases, BCLC: Barcelona Clinic Liver Cancer.